1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
45,00,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 75.38 | 68.82 | 37.59 | 38.55 |
| Total Income | 71.87 | 79.94 | 56.72 | 44.51 |
| Profit After Tax | 5.63 | 7.36 | 4.14 | 0.87 |
| EBITDA | 9.19 | 11.80 | 7.01 | 3.27 |
| NET Worth | 15.62 | 9.99 | 2.63 | -1.50 |
| Reserves and Surplus | 15.32 | 9.69 | 2.33 | -1.80 |
| Total Borrowing | 21.05 | 18.75 | 18.37 | 18.48 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹166.00 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹32.00 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹164.90 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹269.80 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹299.30 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹230.10 |
| Symbiotec Pharmalab Ltd. | Mainboard | ₹1,757.00 Cr | ₹988 | 56.39 | ₹1,097.70 | +11.10% | ₹1,055.75 |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹64.35 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹509.95 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,053.30 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,592.80 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards construction of the proposed corporate office and guest house of the company in Tamil Nadu, India | 4.79 |
| 2 | Funding capital expenditure towards procurement of machineries for expansion and upgradation of the existing manufacturing facility in Puducherry, India | 7.45 |
| 3 | Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings availed by the company | 13.50 |
| 4 | Funding incremental working capital requirements; and | 19.50 |
| 5 | General Corporate Purposes | |
| Total | 45.25 |
About Sai Primus Lifebiotech IPO
Updated on Jun 30, 2026
Contact Details
Sai Primus Lifebiotech Ltd. AddressR.S.No.4/3, Plot No.33KurumbapetPuducherry, Puducherry, 6050090413 - 296631investors@splbiotech.comVisit Website